{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:10:02Z","timestamp":1791943802932,"version":"4.3.4"},"reference-count":27,"publisher":"Society of Nuclear Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,1,7]]},"published-print":{"date-parts":[[2026,5]]},"DOI":"10.2967\/jnumed.125.270789","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:26:52Z","timestamp":1770913612000},"page":"731-738","source":"Crossref","is-referenced-by-count":4,"title":["PSMA PET\/CT\u2013Derived Indicators and Outcomes After [\n                    <sup>177<\/sup>\n                    Lu]Lu-PSMA-617: A Multicenter Retrospective Analysis from the U.S. Expanded-Access Program"],"prefix":"10.2967","volume":"67","author":[{"given":"Koichiro","family":"Kimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F.","family":"Voter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilja B.","family":"Solnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abuzar","family":"Moradi Tuchayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surekha","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lela","family":"Theus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Holzgreve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena M.","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan R.","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Czernin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Gafita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Calais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"2026050105301235000_67.5.731.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026050105301235000_67.5.731.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2026050105301235000_67.5.731.3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268818"},{"key":"2026050105301235000_67.5.731.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06255-8"},{"key":"2026050105301235000_67.5.731.5","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460"},{"key":"2026050105301235000_67.5.731.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00529-6"},{"key":"2026050105301235000_67.5.731.7","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis","volume":"48","author":"Seifert","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026050105301235000_67.5.731.8","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.7150\/thno.47251","article-title":"Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving 177Lu-PSMA-617 radioligand therapy","volume":"10","author":"Seifert","year":"2020","journal-title":"Theranostics."},{"key":"2026050105301235000_67.5.731.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00274-6"},{"key":"2026050105301235000_67.5.731.10","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","article-title":"Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617","volume":"47","author":"Ferdinandus","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026050105301235000_67.5.731.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.265242"},{"key":"2026050105301235000_67.5.731.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267014"},{"key":"2026050105301235000_67.5.731.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.224055"},{"key":"2026050105301235000_67.5.731.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2026050105301235000_67.5.731.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263638"},{"key":"2026050105301235000_67.5.731.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264489"},{"key":"2026050105301235000_67.5.731.17","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1053\/j.gastro.2017.11.008","article-title":"Prognostic utility of total 68Ga-DOTATATE-avid tumor volume in patients with neuroendocrine tumors","volume":"154","author":"Tirosh","year":"2018","journal-title":"Gastroenterology."},{"key":"2026050105301235000_67.5.731.18","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1182\/blood.2019003526","article-title":"High total metabolic tumor volume at baseline predicts survival independent of response to therapy","volume":"135","author":"Vercellino","year":"2020","journal-title":"Blood."},{"key":"2026050105301235000_67.5.731.19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/ajco.14174","article-title":"Prognostic [68Ga]Ga-PSMA-11 PET biomarkers for [177Lu]Lu-PSMA radioligand therapy in metastatic castrate-resistant prostate cancer (Asian population study)","volume":"21","author":"Koh","year":"2025","journal-title":"Asia Pac J Clin Oncol."},{"key":"2026050105301235000_67.5.731.20","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.7150\/thno.60222","article-title":"Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy","volume":"11","author":"Seifert","year":"2021","journal-title":"Theranostics."},{"key":"2026050105301235000_67.5.731.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263441"},{"key":"2026050105301235000_67.5.731.22","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.euo.2018.11.007","article-title":"Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for 177Lu-labelled PSMA radioligand therapy","volume":"2","author":"Thang","year":"2019","journal-title":"Eur Urol Oncol."},{"key":"2026050105301235000_67.5.731.23","unstructured":"Low PSMA SUV boost (LPS-Boost): intensified 177Lu-PSMA-617 treatment for patients with metastatic castrate-resistant prostate cancer with low PSMA expressing disease. U.S. National Library of Medicine website. https:\/\/clinicaltrials.gov\/study\/NCT06526299. Updated November 5, 2025. Accessed November 27, 2025."},{"key":"2026050105301235000_67.5.731.24","doi-asserted-by":"crossref","first-page":"14989","DOI":"10.1038\/s41598-024-65399-1","article-title":"Comparison of digital and analog [68Ga]Ga-PSMA-11 PET\/CT for detecting post-prostatectomy biochemical recurrence in prostate cancer patients: a prospective study","volume":"14","author":"Kim","year":"2024","journal-title":"Sci Rep."},{"key":"2026050105301235000_67.5.731.25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40658-025-00748-1","article-title":"Comparison of 18F-FDG PET image quality and quantitative parameters between DPR and OSEM reconstruction algorithm in patients with lung cancer","volume":"12","author":"Zhang","year":"2025","journal-title":"EJNMMI Phys."},{"key":"2026050105301235000_67.5.731.26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13550-019-0569-7","article-title":"SUV variability in EARL-accredited conventional and digital PET","volume":"9","author":"Koopman","year":"2019","journal-title":"EJNMMI Res."},{"key":"2026050105301235000_67.5.731.27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40658-022-00470-2","article-title":"Method to determine the statistical technical variability of SUV metrics","volume":"9","author":"De Luca","year":"2022","journal-title":"EJNMMI Phys."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:31:06Z","timestamp":1777638666000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,1]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.2967\/jnumed.125.270789"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270789","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}